Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing

Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing

Esophageal squamous cell carcinoma (ESCC) is a deadly disease with a low 5-year survival rate. Anti-epidermal growth factor receptor (EGFR) therapy has been widely used in the treatment of malignancies, and chemotherapy regimens that include nimotuzumab have been confirmed to have satisfactory effic...

Full description

Bibliographic Details
Main Authors: Dantong Sun, Weihua Yan, Hua Zhu, Qiaoling Liu, Helei Hou
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Oncology
Subjects:
nimotuzumab
resistance
PIK3CA
mTOR
PD-L1
esophageal squamous cell carcinoma
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.574523/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.574523/full

Similar Items